Esther Kissling, Marine Maurel, Francisco Pozo, Gloria Pérez-Gimeno, Silke Buda, Noémie Sève, Lisa Domegan, Mariëtte Hooiveld, Beatrix Oroszi, Iván Martínez-Baz, Raquel Guiomar, Neus Latorre-Margalef, Ivan Mlinarić, Mihaela Lazar, Jaume Giménez Duran, Ralf Dürrwald, Vincent Enouf, Adele McKenna, Marit de Lange, Gergő Túri, Camino Trobajo-Sanmartín, Verónica Gomez, Tove Samuelsson Hagey, Vesna Višekruna Vučina, Maria Carmen Cherciu, Miriam García Vazquez, Annika Erdwiens, Shirley Masse, Charlene Bennett, Adam Meijer, Katalin Kristóf, Jesús Castilla, Ana Paula Rodrigues, Sanja Kurečić Filipović, Alina Elena Ivanciuc, Sabrina Bacci, Marlena Kaczmarek
{"title":"流感疫苗在欧洲的有效性和出生队列对甲型H1N1流感的影响：VEBIS初级保健多中心研究，2023/24","authors":"Esther Kissling, Marine Maurel, Francisco Pozo, Gloria Pérez-Gimeno, Silke Buda, Noémie Sève, Lisa Domegan, Mariëtte Hooiveld, Beatrix Oroszi, Iván Martínez-Baz, Raquel Guiomar, Neus Latorre-Margalef, Ivan Mlinarić, Mihaela Lazar, Jaume Giménez Duran, Ralf Dürrwald, Vincent Enouf, Adele McKenna, Marit de Lange, Gergő Túri, Camino Trobajo-Sanmartín, Verónica Gomez, Tove Samuelsson Hagey, Vesna Višekruna Vučina, Maria Carmen Cherciu, Miriam García Vazquez, Annika Erdwiens, Shirley Masse, Charlene Bennett, Adam Meijer, Katalin Kristóf, Jesús Castilla, Ana Paula Rodrigues, Sanja Kurečić Filipović, Alina Elena Ivanciuc, Sabrina Bacci, Marlena Kaczmarek","doi":"10.2807/1560-7917.ES.2025.30.23.2500011","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Europe using a multicentre test-negative study.MethodsPrimary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression.ResultsWe included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44-59). By year of age, VE was 27% (95% CI: -2 to 47) at 44 years with peaks at 72% (95% CI: 52-84) and 54% (95% CI: 41-64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24-54) and -11% (95% CI: -69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20-48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1-62). All-age VE against B/Victoria was 83% (95% CI: 65-94), ranging between 70 and 92% by age group.DiscussionThe 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 23","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164280/pdf/","citationCount":"0","resultStr":"{\"title\":\"Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24.\",\"authors\":\"Esther Kissling, Marine Maurel, Francisco Pozo, Gloria Pérez-Gimeno, Silke Buda, Noémie Sève, Lisa Domegan, Mariëtte Hooiveld, Beatrix Oroszi, Iván Martínez-Baz, Raquel Guiomar, Neus Latorre-Margalef, Ivan Mlinarić, Mihaela Lazar, Jaume Giménez Duran, Ralf Dürrwald, Vincent Enouf, Adele McKenna, Marit de Lange, Gergő Túri, Camino Trobajo-Sanmartín, Verónica Gomez, Tove Samuelsson Hagey, Vesna Višekruna Vučina, Maria Carmen Cherciu, Miriam García Vazquez, Annika Erdwiens, Shirley Masse, Charlene Bennett, Adam Meijer, Katalin Kristóf, Jesús Castilla, Ana Paula Rodrigues, Sanja Kurečić Filipović, Alina Elena Ivanciuc, Sabrina Bacci, Marlena Kaczmarek\",\"doi\":\"10.2807/1560-7917.ES.2025.30.23.2500011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>IntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Europe using a multicentre test-negative study.MethodsPrimary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression.ResultsWe included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44-59). By year of age, VE was 27% (95% CI: -2 to 47) at 44 years with peaks at 72% (95% CI: 52-84) and 54% (95% CI: 41-64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24-54) and -11% (95% CI: -69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20-48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1-62). All-age VE against B/Victoria was 83% (95% CI: 65-94), ranging between 70 and 92% by age group.DiscussionThe 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.</p>\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 23\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164280/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.23.2500011\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.23.2500011","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24.
IntroductionInfluenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.AimThe VEBIS primary care network estimated influenza VE in Europe using a multicentre test-negative study.MethodsPrimary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We estimated VE against influenza (sub)type and clade, by age group and by year of age for A(H1N1)pdm09, using logistic regression.ResultsWe included 29,958 patients, with 3,054, 1,053 and 311 influenza A(H1N1)pdm09, A(H3N2) and B cases, respectively. All-age VE against influenza A(H1N1)pdm09 was 52% (95% CI: 44-59). By year of age, VE was 27% (95% CI: -2 to 47) at 44 years with peaks at 72% (95% CI: 52-84) and 54% (95% CI: 41-64) among children and those 65 years and older, respectively. All-age A(H1N1)pdm09 VE against clade 5a.2a was 41% (95% CI: 24-54) and -11% (95% CI: -69 to 26) against clade 5a.2a.1. The A(H3N2) VE was 35% (95% CI: 20-48) among all ages and ranged between 34% and 40% by age group. All-age VE against clade 2a.3a.1 was 38% (95% CI: 1-62). All-age VE against B/Victoria was 83% (95% CI: 65-94), ranging between 70 and 92% by age group.DiscussionThe 2023/24 VEBIS primary care VE against medically attended symptomatic influenza infection was high against influenza B/Victoria, but lower against influenza A(H1N1)pdm09 and A(H3N2). Clade- and age-specific effects may have played a role in the lower A(H1N1)pdm09 VE.
期刊介绍：
Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
